• H. Lundbeck A/S, of Copenhagen, Denmark, and Otsuka Pharmaceutical Co., Ltd., of Tokyo, said the FDA approved Abilify Maintena (aripiprazole) for extended-release injectable suspension, an intramuscular depot formulation for the treatment of schizophrenia.